NCT05011487View on ClinicalTrials.gov

Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 13, 2021

Primary Completion Date

September 1, 2023

Study Completion Date

September 30, 2028

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Osimertinib

80mg/qd oral for 60 days

DRUG

Cisplatin

Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.

DRUG

Pemetrexed

Pemetrexed (500 mg/m2) to be administered with cisplatin on Day 1 of every 3-week cycle for 2 cycles

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER